HCW Biologics discovers drug candidate prevents lung disease in infants
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- Qtrex Quantum executives plan to buy up to 2M shares over 12 months
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
HCW Biologics Discovers that HCW11-040 Prevents Bronchopulmonary Dysplasia (BPD) During IND-Enabling Studies
May 14, 2026 7:30 AM EDTHCW11-040 is a pembrolizumab-based fusion immunotherapeutic that activates immune cells and eliminates high-oxygen induced senescent cells
BPD is a rare pediatric disease affecting underweight premature infants which the Company believes aligns with newly reauthorized rare pediatric disease and review voucher programs
BPD causes abnormal lung development in premature infants that leads to long-term health problems that persist into adulthood as well as neurodevelopmental delays
MIRAMAR, Fla., May 14, 2026 (GLOBE NEWSWIRE) -- HCW Biologics Inc. (the Company or HCW Biologics), (NASDAQ: HCWB), a... More
